---
title: "U.S. stock night market | iHeartMedia soared 64%, reports say Netflix is in talks with it to license video podcast content"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/264116804.md"
description: "On November 3rd (Tuesday), during the after-hours trading session of the US stock market, iHeartMedia surged 64%, with reports that Netflix is in talks with it to license video podcast content; Hims & Hers Health rose nearly 6%, with third-quarter revenue of $599 million, a year-on-year increase of 49%; Palantir fell 4% in after-hours trading, having once risen 7% post-market, with third-quarter revenue of $1.18 billion, a year-on-year increase of 63%, exceeding analysts' expectations of $1.09 billion. Adjusted earnings per share were $0.21, surpassing the expected $0.17; precision gene leader Sarepta plummeted 36%, as its DMD gene therapy clinical trial did not meet expectations"
datetime: "2025-11-04T01:13:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264116804.md)
  - [en](https://longbridge.com/en/news/264116804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264116804.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/264116804.md) | [繁體中文](https://longbridge.com/zh-HK/news/264116804.md)


# U.S. stock night market | iHeartMedia soared 64%, reports say Netflix is in talks with it to license video podcast content

On November 3rd (Tuesday), during the night trading session of the US stock market, iHeartMedia surged 64%, with reports that Netflix is negotiating to license video podcast content;

Hims & Hers Health rose nearly 6%, with third-quarter revenue of $599 million, a year-on-year increase of 49%;

Palantir fell 4% in after-hours trading, having once risen 7% post-market. Third-quarter revenue was $1.18 billion, a year-on-year increase of 63%, exceeding analysts' expectations of $1.09 billion. Adjusted earnings per share were $0.21, surpassing the expected $0.17;

Precision gene leader Sarepta plummeted 36%, as its DMD gene therapy clinical trial did not meet expectations

### Related Stocks

- [iHeartMedia, Inc. (IHRT.US)](https://longbridge.com/en/quote/IHRT.US.md)
- [Palantir Technologies Inc. (PLTR.US)](https://longbridge.com/en/quote/PLTR.US.md)
- [Hims & Hers Health, Inc. (HIMS.US)](https://longbridge.com/en/quote/HIMS.US.md)
- [Sarepta Therapeutics, Inc. (SRPT.US)](https://longbridge.com/en/quote/SRPT.US.md)

## Related News & Research

- [Ocugen Updates Roadmap for Gene-Agnostic Retinal Therapies](https://longbridge.com/en/news/280790760.md)
- [Neurogene Advances Rett Gene Therapy Toward BLA With Strong Cash Runway](https://longbridge.com/en/news/280377541.md)
- [Lexeo Therapeutics Advances Cardiac Gene Therapies, Strengthens Finances](https://longbridge.com/en/news/281090118.md)
- [Rocket Pharma Wins FDA Approval For KRESLADI — The First Ever Gene Therapy For Severe LAD-I](https://longbridge.com/en/news/280778343.md)
- [06:00 ETTEAMSTERS GENERAL PRESIDENT SEAN M. O'BRIEN TO JOIN STRIKING HENRY FORD GENESYS NURSES](https://longbridge.com/en/news/281164825.md)